Genmab A/S cash flow statement GMAB

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Genmab A/S generated $1.2 billion of cash from operations. It spent $37.0 million on capital expenditures. That left free cash flow of $1.1 billion.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
Operating
Stock-based compensation
128
Operating cash flow
1,186
Investing
Capital expenditures
37
Investing cash flow
-5,643
Financing
Debt issued
5,500
Debt repaid
273
Financing cash flow
4,789
Change in cash
Effect of exchange rate
3
Free cash flow
1,149
Per share
Free cash flow per share
18.33
Ratios
Free cash flow margin
30.89%
Capital expenditures to revenue
0.99%
Stock-based compensation to revenue
3.44%
Cash conversion
1.23x
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
GMAB (Nasdaq), GNMSF (OTC)
Headquarters
1253 Copenhagen K, Denmark
SEC filer status
Large accelerated filer
SEC CIK
1434265

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.